Endocrine Society GUIDELINES Bundle (free trial)

Vitamin D for Prevention of Disease

Endocrine Society GUIDELINES Apps brought to you free of charge courtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/1522405

Contents of this Issue

Navigation

Page 2 of 7

Nonpregnant Adults <50 Years of Age Recommendation 2 ➤ In the general adult population younger than age 50 years, we suggest against empiric vitamin D supplementation. (2| ⊕ ) Technical remark: • This recommendation relates to empiric vitamin D supplementation that exceeds the Dietary Reference Intakes (DRIs) established by the Institute of Medicine (IOM). Adults in this age group should follow the Recommended Daily Allowance established by the IOM (600 IU [15 μg ] daily). Recommendation 3 ➤ In the general adult population younger than age 50 years, we suggest against routine 25(OH)D testing. (2| ⊕ ) Technical remarks: • In this population, 25(OH)D levels that provide outcome-specific benefits have not been established in clinical trials. • The panel suggests against (a) routine screening for a 25(OH)D level to guide decision- making (i.e., vitamin D vs no vitamin D) and (b) routine follow-up testing for 25(OH)D level to guide vitamin D dosing. • This recommendation relates to generally healthy adults who do not otherwise have established indications for 25(OH)D testing (e.g., hypocalcemia). Adults Aged 50–74 Years Recommendation 4 ➤ In the general population ages 50 to 74 years, we suggest against routine vitamin D supplementation. (2|⊕⊕⊕) Technical remark: • This recommendation relates to empiric vitamin D supplementation that exceeds the DRIs established by the IOM. Adults in this age group should follow the Recommended Daily Allowance established by the IOM (600 IU [15 μg] daily for those aged 50 to 70 years; 800 IU [20 μg] daily for those older than 70 years). Recommendation 5 ➤ In the general population ages 50 to 74 years, we suggest against routine 25(OH)D testing. (2| ⊕ ) Technical remarks: • In this population, 25(OH)D levels that provide outcome-specific benefits have not been established in clinical trials. • The panel suggests against (a) routine screening for a 25(OH)D level to guide decision- making (i.e., vitamin D vs no vitamin D) and (b) routine follow-up testing for 25(OH)D level to guide vitamin D dosing. • This recommendation relates to generally healthy adults who do not otherwise have established indications for 25(OH)D testing (e.g., hypocalcemia). Treatment

Articles in this issue

Archives of this issue

view archives of Endocrine Society GUIDELINES Bundle (free trial) - Vitamin D for Prevention of Disease